Cabometyx Approval History
- FDA approved: Yes (First approved April 25th, 2016)
- Brand name: Cabometyx
- Generic name: cabozantinib
- Dosage form: Tablets
- Company: Exelixis, Inc.
- Treatment for: Renal Cell Carcinoma
Cabometyx (cabozantinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
The FDA approval of Cabometyx was based on results of the phase 3 METEOR trial which included 658 patients with advanced renal cell carcinoma who had failed at least one prior VEGF receptor tyrosine kinase inhibitor therapy. Patients were randomized 1:1 to receive 60 mg of Cabometyx daily or 10 mg of everolimus daily. Compared with everolimus, Cabometyx was associated with a 42 percent reduction in the rate of disease progression or death. Median progression-free survival for cabozantinib was 7.4 months versus 3.8 months for everolimus.
Cabometyx tablets are taken once daily without food. Cabometyx must not be substituted for the capsule form of cabozantinib (Cometriq), which is a different formulation approved for the treatment of medullary thyroid cancer.
The most common side effects reported in clinical trials include diarrhea, fatigue, nausea, decreased appetite, hand-foot syndrome, high blood pressure, vomiting, weight loss, and constipation.
Development History and FDA Approval Process for Cabometyx
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.